Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Therapy and Pembrolizumab in Metastatic Melanoma
NCT03325101Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Intus in melanoma, sponsored by Mayo Clinic. Started Nov 2017; status: terminated.
02
Drugs
Intus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03325101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325101.